Role of TGF-β signaling in uterine carcinosarcoma

Shailendra Kumar Dhar Dwivedi, Scott D. McMeekin, Katrina Slaughter, Resham Bhattacharya

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Uterine carcinosarcomas (UCS) are rare (3-4%) but highly aggressive, accounting for a disproportionately high (16.4%) mortality among uterine malignancies. Transforming growth factor beta (TGFβ) is a multifunctional cytokine that regulates important cellular processes including epithelial-mesenchymal transition (EMT). Existence of biphasic elements and a report demonstrating amplification of TGFβ at 19q13.1 prompted us to investigate the role of TGFβ signaling in UCS. Here we demonstrated the components of TGFβ pathway are expressed and functional in UCS. TGFβ-I induced significant Smad2/3 phosphorylation, migration and EMT responses in UCS cell lines which could be attenuated by the TGFβ receptor I (TGFβR-I) or TGFβ receptor I/II (TGFβR-I/II) inhibitor developed by Eli Lilly and company. Importantly, TGFβ-I induced proliferation was c-Myc dependent, likely through activation of cell cycle. c-Myc was induced by nuclear translocation of nuclear factor of activated T cells (NFAT-1) in response to TGFβ-I. Inhibition of NFAT-1 or TGFβR-I blocked c-Myc induction, cell cycle progression and proliferation in UCS. In corroboration, mRNA levels of c-Myc were elevated in recurrent versus the nonrecurrent UCS patient samples. Interestingly, in the absence of exogenous TGFβ the TGFβR-I/II inhibitor enhanced proliferation likely through non-Smad pathways. Thus, inhibition of TGFβR-I could be efficacious in treatment of UCS.

Original languageEnglish (US)
Pages (from-to)14646-14655
Number of pages10
JournalOncotarget
Volume6
Issue number16
StatePublished - 2015
Externally publishedYes

Fingerprint

Carcinosarcoma
Transforming Growth Factor beta
Transforming Growth Factor beta1
Epithelial-Mesenchymal Transition
Cell Cycle
NFATC Transcription Factors
Phosphorylation
Cell Proliferation
Cytokines
Cell Line
Messenger RNA
Mortality

Keywords

  • C-Myc
  • EMT
  • TGF beta
  • Uterine carcinosarcoma

ASJC Scopus subject areas

  • Oncology

Cite this

Dhar Dwivedi, S. K., McMeekin, S. D., Slaughter, K., & Bhattacharya, R. (2015). Role of TGF-β signaling in uterine carcinosarcoma. Oncotarget, 6(16), 14646-14655.

Role of TGF-β signaling in uterine carcinosarcoma. / Dhar Dwivedi, Shailendra Kumar; McMeekin, Scott D.; Slaughter, Katrina; Bhattacharya, Resham.

In: Oncotarget, Vol. 6, No. 16, 2015, p. 14646-14655.

Research output: Contribution to journalArticle

Dhar Dwivedi, SK, McMeekin, SD, Slaughter, K & Bhattacharya, R 2015, 'Role of TGF-β signaling in uterine carcinosarcoma', Oncotarget, vol. 6, no. 16, pp. 14646-14655.
Dhar Dwivedi SK, McMeekin SD, Slaughter K, Bhattacharya R. Role of TGF-β signaling in uterine carcinosarcoma. Oncotarget. 2015;6(16):14646-14655.
Dhar Dwivedi, Shailendra Kumar ; McMeekin, Scott D. ; Slaughter, Katrina ; Bhattacharya, Resham. / Role of TGF-β signaling in uterine carcinosarcoma. In: Oncotarget. 2015 ; Vol. 6, No. 16. pp. 14646-14655.
@article{840cee92492c4da987e1c194831e4b2d,
title = "Role of TGF-β signaling in uterine carcinosarcoma",
abstract = "Uterine carcinosarcomas (UCS) are rare (3-4{\%}) but highly aggressive, accounting for a disproportionately high (16.4{\%}) mortality among uterine malignancies. Transforming growth factor beta (TGFβ) is a multifunctional cytokine that regulates important cellular processes including epithelial-mesenchymal transition (EMT). Existence of biphasic elements and a report demonstrating amplification of TGFβ at 19q13.1 prompted us to investigate the role of TGFβ signaling in UCS. Here we demonstrated the components of TGFβ pathway are expressed and functional in UCS. TGFβ-I induced significant Smad2/3 phosphorylation, migration and EMT responses in UCS cell lines which could be attenuated by the TGFβ receptor I (TGFβR-I) or TGFβ receptor I/II (TGFβR-I/II) inhibitor developed by Eli Lilly and company. Importantly, TGFβ-I induced proliferation was c-Myc dependent, likely through activation of cell cycle. c-Myc was induced by nuclear translocation of nuclear factor of activated T cells (NFAT-1) in response to TGFβ-I. Inhibition of NFAT-1 or TGFβR-I blocked c-Myc induction, cell cycle progression and proliferation in UCS. In corroboration, mRNA levels of c-Myc were elevated in recurrent versus the nonrecurrent UCS patient samples. Interestingly, in the absence of exogenous TGFβ the TGFβR-I/II inhibitor enhanced proliferation likely through non-Smad pathways. Thus, inhibition of TGFβR-I could be efficacious in treatment of UCS.",
keywords = "C-Myc, EMT, TGF beta, Uterine carcinosarcoma",
author = "{Dhar Dwivedi}, {Shailendra Kumar} and McMeekin, {Scott D.} and Katrina Slaughter and Resham Bhattacharya",
year = "2015",
language = "English (US)",
volume = "6",
pages = "14646--14655",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "16",

}

TY - JOUR

T1 - Role of TGF-β signaling in uterine carcinosarcoma

AU - Dhar Dwivedi, Shailendra Kumar

AU - McMeekin, Scott D.

AU - Slaughter, Katrina

AU - Bhattacharya, Resham

PY - 2015

Y1 - 2015

N2 - Uterine carcinosarcomas (UCS) are rare (3-4%) but highly aggressive, accounting for a disproportionately high (16.4%) mortality among uterine malignancies. Transforming growth factor beta (TGFβ) is a multifunctional cytokine that regulates important cellular processes including epithelial-mesenchymal transition (EMT). Existence of biphasic elements and a report demonstrating amplification of TGFβ at 19q13.1 prompted us to investigate the role of TGFβ signaling in UCS. Here we demonstrated the components of TGFβ pathway are expressed and functional in UCS. TGFβ-I induced significant Smad2/3 phosphorylation, migration and EMT responses in UCS cell lines which could be attenuated by the TGFβ receptor I (TGFβR-I) or TGFβ receptor I/II (TGFβR-I/II) inhibitor developed by Eli Lilly and company. Importantly, TGFβ-I induced proliferation was c-Myc dependent, likely through activation of cell cycle. c-Myc was induced by nuclear translocation of nuclear factor of activated T cells (NFAT-1) in response to TGFβ-I. Inhibition of NFAT-1 or TGFβR-I blocked c-Myc induction, cell cycle progression and proliferation in UCS. In corroboration, mRNA levels of c-Myc were elevated in recurrent versus the nonrecurrent UCS patient samples. Interestingly, in the absence of exogenous TGFβ the TGFβR-I/II inhibitor enhanced proliferation likely through non-Smad pathways. Thus, inhibition of TGFβR-I could be efficacious in treatment of UCS.

AB - Uterine carcinosarcomas (UCS) are rare (3-4%) but highly aggressive, accounting for a disproportionately high (16.4%) mortality among uterine malignancies. Transforming growth factor beta (TGFβ) is a multifunctional cytokine that regulates important cellular processes including epithelial-mesenchymal transition (EMT). Existence of biphasic elements and a report demonstrating amplification of TGFβ at 19q13.1 prompted us to investigate the role of TGFβ signaling in UCS. Here we demonstrated the components of TGFβ pathway are expressed and functional in UCS. TGFβ-I induced significant Smad2/3 phosphorylation, migration and EMT responses in UCS cell lines which could be attenuated by the TGFβ receptor I (TGFβR-I) or TGFβ receptor I/II (TGFβR-I/II) inhibitor developed by Eli Lilly and company. Importantly, TGFβ-I induced proliferation was c-Myc dependent, likely through activation of cell cycle. c-Myc was induced by nuclear translocation of nuclear factor of activated T cells (NFAT-1) in response to TGFβ-I. Inhibition of NFAT-1 or TGFβR-I blocked c-Myc induction, cell cycle progression and proliferation in UCS. In corroboration, mRNA levels of c-Myc were elevated in recurrent versus the nonrecurrent UCS patient samples. Interestingly, in the absence of exogenous TGFβ the TGFβR-I/II inhibitor enhanced proliferation likely through non-Smad pathways. Thus, inhibition of TGFβR-I could be efficacious in treatment of UCS.

KW - C-Myc

KW - EMT

KW - TGF beta

KW - Uterine carcinosarcoma

UR - http://www.scopus.com/inward/record.url?scp=84931033622&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84931033622&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84931033622

VL - 6

SP - 14646

EP - 14655

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 16

ER -